Bio-Rad Laboratories, Inc. (BIO) News
Filter BIO News Items
BIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIO News Highlights
- For BIO, its 30 day story count is now at 27.
- Over the past 15 days, the trend for BIO's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- RAD, AMN and BAX are the most mentioned tickers in articles about BIO.
Latest BIO News From Around the Web
Below are the latest news stories about Bio-Rad Laboratories Inc that investors may wish to consider to help them evaluate BIO as an investment opportunity.
Bio-Rad Laboratories Up 7% After Investor Dayhttps://www.investing.com/news/stock-market-news/biorad-laboratories-up-7-after-investor-day-2772756 |
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor DayHERCULES, Calif., February 25, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad’s executive leadership team will provide an in-depth overview of the Company’s growth strategy and new long-term financial targets, as well a closer look at the drivers within the two core business segments – Life |
Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin ImprovesStrength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment. |
Here's How Much You'd Have If You Invested $1000 in Bio-Rad Laboratories a Decade AgoInvesting in certain stocks can pay off in the long run, especially if you hold on for a decade or more. |
Integra's (IART) Q4 Earnings Top Estimates, Gross Margin DropsIntegra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring. |
Insulet (PODD) Q4 Earnings Surpass Estimates, Margins UpInsulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets. |
NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin UpContinued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021. |
Cerner (CERN) Q4 Earnings Surpass Estimates, Revenues MissCerner's (CERN) fourth-quarter results benefit from gains across four of its business units. |
LHC Group (LHCG) Q4 Earnings Miss Estimates, Revenues BeatDespite the weak bottom-line performance, LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health admissions. |
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/YFresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments. |